Compare Abeona Therapeutics Inc (ABEO) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Live Nation Entertainment, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Live Nation Entertainment, Inc. trades at $182.39 (market cap $42.80B). The key difference: Live Nation Entertainment, Inc. is far larger — about 114.6× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | LYV | |
|---|---|---|
Market Cap | $373.32M | $42.80B |
Sector | Health | Industrials |
52-Week High | $7.23 | $186.59 |
52-Week Low | $4.17 | $125.61 |
Enterprise Value | $228.22M | $44.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Live Nation (LYV) trades at $183.92, down 1.43% with a bullish technical signal despite recent earnings misses. The stock shows strong analyst support with 88.6% buy ratings and a $194 consensus target. Revenue growth remains solid at $25.2B for 2025, though profitability metrics are weak with a 0.33% net margin and negative ROE. Recent news highlights strong concert demand and strategic initiatives.
Outlook remains positive driven by live event recovery and ticketing dominance, but elevated valuation ratios and profitability challenges present risks. The stock faces headwinds from legal expenses and consumer spending pressures, requiring careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
